PRESS-RELEASE ·Filed Apr 21, 2026

AUTL

Autolus Therapeutics plc
NEUTRAL
Impact 3/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release: activist
Actionable Insight • Neutral

Monitor future 10-Q filings for incremental share count changes and stock-based compensation expenses. This is a routine hiring incentive and not a material event; no immediate trading implication.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
AUTL ▼ -10.00% at T+60d
NEUTRAL call ✗ call lost -10.00% · α vs SPY -14.78% · entry $1.60 → $1.44
Entry anchored
Apr 21, 03:59 PM ET
via exchange tick
T+1d
-4.38%
call -4.38% · α -3.98%
$1.53
settled 5mo ago
T+5d
-11.56%
call -11.56% · α -11.62%
$1.42
settled 5mo ago
T+20d
+1.88%
call +1.88% · α -1.29%
$1.63
settled 5mo ago
T+60d
-10.00%
call -10.00% · α -14.78%
$1.44
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Autolus Therapeutics granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees as inducement awards under its 2025 Inducement Plan. The awards, priced at $1.47 per share, vest over four years and are intended to attract talent, but represent a minor dilutive impact.

Key Facts

  • Granted stock options for 68,500 ADSs and 57,765 RSUs to 15 new employees
  • Awards made under Nasdaq Listing Rule 5635(c)(4) as inducement grants
  • Exercise price of $1.47 equals closing price on April 13, 2026
  • Options vest over four years (25% at year one, then monthly); RSUs vest in four equal annual installments
  • No financial performance metrics or material business developments disclosed

Financial Impact

Approximately 126,265 shares subject to awards, representing ~0.3% of Autolus' current market cap ($421M) if fully diluted at $1.47/share

dilutionshare_countcompensation_expense

Risk Factors

  • Potential for modest dilution upon exercise of options and vesting of RSUs
  • Inducement grants may signal aggressive hiring in a cash-intensive phase, increasing burn rate

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278431
13 reports for AUTL
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +29.12%Aug 3, 2026
Filters
Rows
Reports for AUTL — sortable, filterable
TypeNow
Sep 12, 2026
20d ago
S-3
NEUTRAL ★ 4/10
$1.94 $1.94· 0.00%▼ −0.11%$1.78 (−8.25%)
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$2.33 $2.29▼ −1.72%▼ −1.31%$1.78 (−23.61%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 7/10
$1.82 $2.07▲ +13.74%▲ +11.71%$1.78 (−2.20%)
Aug 3, 2026
8w ago
8-K
NEUTRAL ★ 6/10
$1.82 $2.07▲ +13.74%▲ +11.71%$1.78 (−2.20%)
Jun 12, 2026
16w ago
Press Release
NEUTRAL ★ 3/10
$1.56 $1.51▼ −3.21%▼ −3.88%$1.78 (+14.10%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 6/10
$1.56 $1.53▲ +1.92%▲ +2.36%$1.78 (−14.10%)
Jun 9, 2026
16w ago
8-K
BEARISH ★ 7/10
$1.46 $1.50▼ −2.74%▼ −0.33%$1.78 (−21.92%)
May 21, 2026
19w ago
Press Release
NEUTRAL ★ 4/10
$1.70 $1.84▲ +8.24%▲ +6.58%$1.78 (+4.71%)
May 14, 2026
20w ago
8-K
MIXED ★ 6/10
$1.59 $1.65▲ +3.77%▲ +4.49%$1.78 (+11.95%)
May 14, 2026
20w ago
Press Release
MIXED ★ 6/10
$1.59 $1.65▲ +3.77%▲ +4.49%$1.78 (+11.95%)
Showing 10 of 13

US Market Status

Market Closed — Opens Mon (38h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 21, 2026